Prostate cancer therapy could cause cataracts

Article

Androgen deprivation therapy (ADT) used for prostate cancer treatment could contribute towards the development of cataracts.

An investigation by Dr Jennifer Beebe-Dimmer et al, Karmanos Cancer Institute in Detroit, Michigan, USA, has shown that androgen deprivation therapy (ADT) used for prostate cancer treatment could contribute towards the development of cataracts.

ADT has already been proven to increase the chances of developing diabetes and other heart problems.

The study included 66000 prostate cancer patients aged 66 or older from a US cancer registry. Almost half of the patients were treated by ADT within six months of diagnosis. For every 1000 patients studied, 111 cataracts were diagnosed.

The men treated with ADT had an average of 9% increased risk of developing cataracts. This rose by about 26% for the men who had their testicles removed.

In conclusion, it was estimated that 5% of cataract cases in patients with prostate cancer could be attributed to ADT.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Andreas Pollreisz, MD, discusses widefield OCT-A and fluorescence angiography at the 2025 European Society of Retina Specialists EURETINA meeting
Harvey Uy, MD, DPBO, FVRSP, speaks about artificial intelligence (AI) and optical coherence tomography (OCT) at the 2025 European Society of Retina Specialists (EURETINA) Congress.
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
© 2025 MJH Life Sciences

All rights reserved.